Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus maintains 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These 2 pending office actions are distributed across 2 distinct examiners and 2 distinct art units. MOORE, SUSANNA is the busiest examiner for the company, currently responsible for 1 busiest examiner pending action. The presence of 2 distinct art units suggests a diversification in the technical focus of the pending applications.
With 2 distinct examiners involved, the prosecution strategy must account for different individual perspectives within the Biotechnology & Pharmaceuticals sector. This distribution across 2 distinct art units indicates that the company is pursuing multiple technical paths. The workload is split such that MOORE, SUSANNA handles 1 busiest examiner pending action. This variety in examiners and art units requires the applicant to manage separate streams of feedback. Practitioners should prepare for different examination styles given the involvement of 2 distinct examiners. The 2 pending office actions represent the entirety of the current active prosecution for this entity.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MOORE, SUSANNA | 1 | 68.0% | +31.6% |
| NICKOL, GARY B | 1 | 46.6% | +33.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18280104 | BISPECIFIC ANTIBODIES ENHANCING CELL MEDIATED IMMUNE RESPONSES | NICKOL, GARY B | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18280370 | THERAPEUTIC COMBINATIONS INCLUDING INHIBITORS OF THE P2X4 RECEPTOR FOR TREATING AND PREVENTING PROLIFERATIVE DISORDERS | MOORE, SUSANNA | — |
| 18280104 | BISPECIFIC ANTIBODIES ENHANCING CELL MEDIATED IMMUNE RESPONSES | NICKOL, GARY B | — |
| Art Unit | Apps |
|---|---|
| 1624 | 1 |
| 1643 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18280370 | THERAPEUTIC COMBINATIONS INCLUDING INHIBITORS OF THE P2X4 RECEPTOR FOR TREATING AND PREVENTING PROLIFERATIVE DISORDERS | MOORE, SUSANNA | 1624 | §103 | Final Rejection | — | Pending | Sep 05, 2023 |
| 18280104 | BISPECIFIC ANTIBODIES ENHANCING CELL MEDIATED IMMUNE RESPONSES | NICKOL, GARY B | 1643 | §102§103§112 | Non-Final OA | — | Pending | Sep 01, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialChemotherapeutisches Forschungsinstitut Georg-Speyer-Haus has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Susanna Moore has the most, with 1 of Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
